Amazon, Fleming Initiative Partner to Combat Antimicrobial Resistance

The Fleming Initiative announced it will receive support from Amazon Web Services (AWS) to help power its global antimicrobial resistance (AMR) intelligence platform, according to a news release.¹ With the much-needed backing of a global corporation, the initiative can better connect stakeholders with the necessary data to address the growing prominence of AMR.

“The Fleming Initiative’s planned AMR intelligence platform, powered by AWS, has the potential to equip pharmacists and the broader health care community with better insights to understand emerging resistance signals and serve their patients,” Alison Holmes, director of the Fleming Initiative, told Drug Topics® in an exclusive interview. “Pharmacists are on the front lines of the fight against AMR, one of the biggest public health challenges today.”

Prior to bringing AWS into the mix, the Fleming Initiative was formed as a partnership between the Imperial College London and Imperial College Healthcare NHS Trust. Now, with support from an increasingly major player in health care and technology, representatives of the initiative believe this partnership will uncover a myriad of opportunities in the AMR space.¹

READ MORE: Antimicrobial Pharmacists Optimize Antibiotic Use to Mitigate Resistance

The collaborative platform centers on a cloud-based infrastructure designed to integrate previously fragmented datasets, such as compound libraries and surveillance signals. This infrastructure aims to uncover patterns that were once invisible across national and institutional boundaries, facilitating a faster transition from data collection to medical discovery.

By utilizing Amazon Bedrock, the initiative can manage high-performing foundation models to conduct in silico research, potentially accelerating insights that previously took years to generate. This technological leap is critical as AMR is recognized as one of the most urgent public health problems worldwide.^1,2

The Growing Prominence of AMR

According to the CDC, AMR occurs when bacteria and fungi develop mechanisms to defeat the drugs designed to kill them, leading to infections that are difficult or even impossible to treat. In the US alone, more than 2.8 million resistant infections occur annually, resulting in over 35,000 deaths.²

Globally, the situation is even more dire, with deaths associated with AMR predicted to reach nearly 39 million between 2025 and 2050. Researchers have labeled this burgeoning crisis the “silent pandemic,” warning that if left unchecked, AMR could surpass all other causes of mortality by midcentury.^1,3

Microbes employ various strategies to resist treatment, including producing enzymes to destroy antibiotics, using pumps to remove drugs from their cells, and modifying their own genetic targets so medications can no longer bind to them. These defense mechanisms are often shared between different types of germs through horizontal gene transfer, allowing resistance to spread rapidly through microbial populations.^2,3

As standard treatments fail, the absence of effective antimicrobials makes routine procedures like surgeries, organ transplants, and chemotherapy significantly more dangerous.³

Where Pharmacists Come Into Play

For pharmacists, this intelligence platform provides essential support for their growing responsibilities in antimicrobial stewardship programs (ASPs). Clinical pharmacists are uniquely positioned as medication experts to evaluate literature and make evidence-based recommendations on drug selection, dosing, and duration.^4,5

A systematic review of pharmacist-led interventions found that their participation in ASP teams significantly improves antibiotic prescribing, reduces the time to optimal therapy, and optimizes patient outcomes. Pharmacists leverage their knowledge of pharmacokinetics and pharmacodynamics to ensure patients receive appropriate dosing, particularly in complex cases such as critically ill patients in the intensive care unit.

Beyond technology, the fight against AMR requires a “one health” approach that coordinates efforts across human, animal, and environmental health. Although the drug development pipeline has historically been slow, new weapons have recently emerged, including the FDA approvals of ceftobiprole, pivmecillinam, and sulbactam-durlobactam.^3,5

By pairing these new therapies with global data intelligence, the health care community can move from reacting to threats to anticipating them. As pharmacists continue to lead de-escalation programs and educate both colleagues and patients, this integrated platform promises to be a vital tool in preserving the efficacy of current and future antibiotics for generations to come.^1,4

“[Pharmacists] are the ones counseling patients, reviewing prescriptions, and making real-time decisions about treatments that may no longer work the way they once did,” concluded Holmes. “By connecting previously fragmented data at a global scale, we can support a more cohesive, coordinated response to this growing threat.”

READ MORE: Infectious Disease Resource Center

REFERENCES

1. Fleming Initiative selects AWS to power global intelligence platform to tackle antimicrobial resistance. News Release. Fleming Initiative. June 30, 2026. Accessed July 1, 2026. https://www.fleminginitiative.org/post/fleming-initiative-selects-aws-to-power-global-intelligence-platform-to-tackle-amr

2. About antimicrobial resistance. CDC. January 31, 2025. Accessed July 1, 2026. https://www.cdc.gov/antimicrobial-resistance/about/index.html

3. Ahmed SK, Husein S, Qurbani K, et al. Antimicrobial resistance: impacts, challenges, and future prospects. J Med Surg Public Health. 2024;2:100081. https://doi.org/10.1016/j.glmedi.2024.100081

4. Dighriri IM, Alnomci BA, Aljahdali MM, et al. The role of clinical pharmacists in antimicrobial stewardship programs (ASPs): a systematic review. Cureus. 2023 Dec 8;15(12):e50151. doi: 10.7759/cureus.50151.

5. Donaldson JC, Mefford BM. The pharmacist’s role in antimicrobial stewardship. US Pharmacist. October 17, 2024. Accessed July 1, 2026. https://www.uspharmacist.com/article/the-pharmacists-role-in-antimicrobial-stewardship